Trupanion (NASDAQ:TRUP) Full Year 2023 Results
Key Financial Results
- Revenue: US$1.11b (up 23% from FY 2022).
- Net loss: US$44.7m (flat on FY 2022).
- US$1.08 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Trupanion EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Insurance industry in the US.
Performance of the American Insurance industry.
The company's shares are up 21% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Trupanion you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Trupanion might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:TRUP
Trupanion
Provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia.
Excellent balance sheet with reasonable growth potential.